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RESEARCH ARTICLE Open Access
Long-term survival outcomes of HIV
infected children receiving antiretroviral
therapy: an observational study from
Zambia (2003–2015)
Jane N. Mutanga1,2,6* , Simon Mutembo2,3,6, Amara E. Ezeamama4, Xiao Song2, Robert C. Fubisha1,
Kunda Mutesu-Kapembwa1, Derrick Sialondwe1, Brenda Simuchembu1, Jelita Chinyonga3, Philip E. Thuma5
and Christopher C. Whalen2,6
Abstract
Background: In 2017, 64% of children living with HIV in Zambia accessed Antiretroviral Therapy (ART). Despite
expanded ART coverage, there is paucity of information on effectiveness of pediatric ART in reducing mortality. The
aim of this research is to describe treatment outcomes, measure mortality rates and assess predictors of mortality
among children receiving ART.
Methods: Using a retrospective cohort study design, we abstracted routinely collected clinical data from medical
records of children from birth to 15 years old, who had received ART for at least 6 months at Livingstone Central
Hospital in Southern Province Zambia, between January 2003 and June 2015. The primary outcome was death.
Cause of death was ascertained from medical records and death certificates. Distribution of survival times according
to baseline covariates were estimated using Kaplan Meier and Cox Proportional Hazards methods.
Results: Overall, 1039 children were commenced on ART during the study period. The median age at treatment
initiation was 3.6 years (IQR: 1.3–8.6) and 520 (50%) children were female. Of these, 71 (7%) died, 164 (16%) were
lost to follow-up, 210 (20%) transferred and 594 (56%) were actively on treatment. After 4450 person years, mortality
rate was 1.6/100 (95% CI: 1.4–1.8). Mortality was highest during the first 3 months of treatment (11.7/100 (95% CI: 7.
6–16.3). In multivariable proportional hazards regression, the adjusted hazards of death were highest among
children aged < 1 year (aHR = 3.1 (95% CI: 1.3–6.4), compared to those aged 6–15 years, WHO stage 4 (aHR =4.8
(95% CI: 2.3–10), compared to WHO stage 1 and 2. In the sensitivity analysis to address bias due to loss to follow-
up, mortality increased 5 times when we assumed that all the children who were lost to follow up died within 90
days of their last visit.
Conclusion: We observed low attrition due to mortality among children on ART. Loss to follow-up was high (16%).
Mortality was highest during the first 3 months of treatment. Children aged less than one year and those with
advanced WHO disease stage had higher mortality. We recommend effective interventions to improve retention in
care and early diagnosis of HIV in children.
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Background
The availability of Antiretroviral Therapy (ART) for chil-
dren living with HIV and implementation of universal
treatment of all pregnant and breastfeeding women liv-
ing with HIV (Option B+) is a game changer in the glo-
bal fight against HIV [1]. In 2017, about 1.8 million
children were living with HIV globally and 90% of these
children lived in sub-Saharan Africa [2, 3]. Although
progress has been reported in the scale-up of access to
treatment for children, only 52% of children living with
HIV received lifesaving ART and only 51% of
HIV-exposed infants were tested for HIV by the age of
2 months as recommended by the World Health
Organization (WHO) guidelines [2]. These estimates fall
short of the UNAIDS 90–90-90 treatment targets, a
strategy to end the global HIV epidemic. This strategy
aims to achieve the following by 2020: 1) 90% of people
living with HIV will know their status, 2) 90% of all diag-
nosed people will be on ART, 3) 90% of people on ART
will be virally suppressed [4]. Although some milestones
have been achieved in the provision of ART, access to
early HIV diagnosis and ART among infants and chil-
dren remains a challenge in high HIV burden settings
[2, 5].
Similarly, the pediatric HIV program in Zambia has
made tremendous progress with over 64% of children
living with HIV accessing ART by the end of 2017 [6].
With a population of 17 million people and an estimated
HIV prevalence of 12.9%, 72,000 were children living
with HIV and 8900 were newly infected in 2017 [6, 7].
This scenario creates a large pool of children living with
HIV in need of treatment. An early study done in rou-
tine care settings in Zambia demonstrated that children
were diagnosed at older ages with advanced WHO stage
3 or 4 disease. The same study reported that 57% of
deaths occurred within the first 90 days of treatment ini-
tiation and loss to follow-up was high [8]. Early mortal-
ity was consistently associated with lower CD4 count,
younger age, low weight for height and anemia at ART
initiation [8–10]. Recent studies suggest that routine
care settings in resource limited settings are still con-
fronted with critical gaps in early infant diagnosis and
pediatric HIV treatment, resulting in children initiating
treatment with advanced disease and at high risk of
death during the first 3–6 months of treatment [11, 12].
In addition, there are concerns around interpretation of
treatment outcomes in routine care settings because of
the high loss to follow-up and high numbers of transfers
with no mortality ascertainment [11, 13].
Although, pediatric HIV treatment programs in re-
source limited settings like Zambia have been treating
large numbers of HIV-exposed and infected children for
over 15 years, long-term survival and associated factors
including barriers to long-term adherence and retention
in care are not adequately elucidated and therefore the
wider impact of these interventions is not clearly under-
stood [14–16]. The aim of this research is to describe
treatment outcomes, measure mortality rates and assess
predictors of mortality among children receiving ART in
a routine care setting over a 12-year period (2003–2015)
at Livingstone Central Hospital in Southern Province,
Zambia.
Methods
Using a retrospective cohort study design, we evaluated
treatment outcomes among children living with HIV
who received ART between January 2003 and June 2015.
Study setting and population
The data were collected from the Pediatric Center of Ex-
cellence clinic (PCOE) at Livingstone Central Hospital
(LCH) in Southern Province, Zambia. Livingstone Cen-
tral Hospital offers preventive and treatment services to
nearly 1.2 million people in southern and western parts
of Zambia. Pediatric HIV treatment at LCH was started
in 2003 in line with national policy and in 2006 the
PCOE clinic was established through a collaborative
agreement between the Ministry of Health in Zambia
and the Centers for Diseases Control and prevention
country office (CDC) [15].
The Ministry of Health in Zambia began implementa-
tion of the WHO guidelines of treating all people who
test positive for HIV in 2016. The pediatric HIV testing
and treatment guidelines recommended collection of
dried blood spots (DBS) cards for DNA-PCR from all
HIV-exposed infants at birth, 6 weeks and 6months of
age followed by serologic testing at 9 months, 12
months, 18 months and 3months after cessation of
breastfeeding [17]. Dried blood spots cards were col-
lected from all children who were still breastfeeding and
had HIV positive serologic tests, for confirmatory testing
with HIV DNA-PCR. Routine provider initiated counsel-
ing and testing was offered to guardians of all hospital-
ized children. Prior to 2016, pediatric HIV treatment
guidelines recommended ART based on clinical and im-
munological criteria. First line ART regimens comprised
of three antiretroviral medicines including two Nucleo-
side reverse transcriptase inhibitors (NRTI’s): Azido thy-
midine, Stavudine, Abacavir, (Tenofovir for children
above 10 years old) and Lamivudine, plus one
Non-Nucleoside Reverse Transcriptase Inhibitor
(NNRTI), either Nevirapine or Efavirenz for ART naïve
infants and children. Infants who took ART prophylaxis
after delivery were commenced on Protease inhibitors
(PI) based regimens (Lopinavir boosted with Ritonavir)
in addition to two NRTIs. Triple NRTI based regimens
were recommended for children below 3months of age
who were co-infected with Tuberculosis at baseline.
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Patient data were abstracted from the medical records
of children living with HIV who had received ART. The
inclusion criteria were: all children aged from birth to 15
years at the time of ART initiation, children who had
taken ART for 6months or more, children who had re-
ceived at least three ARVs. Children who received one
antiretroviral drug for PMTCT were excluded from the
study because we considered ART to be a combination of
at least three antiretroviral drugs. We excluded children
who started ART on or after December 31st 2014 because
data collection was closed on June 30th 2015 and we in-
cluded only children who took ART for at least 6 months.
Data collection
We abstracted routinely collected data from patient
medical records into a Microsoft access database. We
abstracted the data starting with initial patient enroll-
ment forms which included demographics such as date
of birth, gender, date of first HIV test, mode of delivery
and date when they started to take ART. We assigned
unique study identification numbers to each patient rec-
ord. Data abstraction was done independently by two
data entry clerks and their entries were verified at ran-
dom intervals by a supervisor.
Study outcomes
The main outcome was death. We ascertained death
from hospital medical records. We actively searched for
death certificates and other documentation on the de-
tails of death in medical records. In some cases, details
of death were verified by verbal reports from the child’s
adult family members or care givers.
The secondary outcomes were: 1) Lost to follow-up,
and 2) Transferred to another facility. Lost to follow-up
was defined as no clinical contact for more than
3 months after they missed their last scheduled appoint-
ment. Patients who missed appointments for more than
90 days were visited by a clinic nurse and their status
established. All the children who were lost to follow-up
or transferred were censored on the day of their last visit
to the clinic. Children who survived to the end of the
study were censored on June 30th, 2015. Adolescents
were censored on the date they transitioned into the
adolescent clinic and were no longer seen in the
pediatric clinic at 15 years of age.
Exposure
The main exposure was initiation of ART. Since this was
a retrospective cohort study, the decision to initiate ART
was made by the treating physician and the child’s care-
givers and not influenced by the study investigators. Co-
variates that were abstracted included: ART start date,
the initial drug regimen and baseline laboratory mea-
surements which included hemoglobin, CD4+ count or
CD4+ percentage. Additionally, WHO clinical stage and
anthropometric measurements were abstracted.
Statistical analysis
Baseline demographics and clinical features were de-
scribed by estimating medians and interquartile ranges for
continuous variables and frequencies and proportions for
categorical variables. Observed survival was defined as the
duration of time in years from the date of ART initiation
to the date of death or censoring. We estimated the distri-
bution of survival times for the baseline covariates affect-
ing survival using the Kaplan-Meier (KM) method. The
covariates were selected apriori from literature supported
by a directed acyclic model (Additional file 1). Log-rank
tests were used to compare the survival curves. Cox Pro-
portional Hazards models were used to estimate the haz-
ard ratios for death and their 95% confidence intervals to
quantify the associations. We evaluated the proportional
hazards assumption using log-log plots and plots of
Schoenfeld’s residuals and no violations of the assumption
were found. To calculate the mortality rates, we estimated
the actual person time that everyone contributed to the
study during the first 6months, 1 year, 2 years, 5 years and
10 years and constructed confidence intervals.
Multivariable Cox models were used to adjust for pos-
sible confounding. All p-values were two tailed. In the ana-
lysis, age was a categorical variable with 3 levels. The age
categorization was based on findings from previous studies
which demonstrated that infants aged less than 12months
had a different survival experience based on disease pro-
gression [5, 18]. WHO stage was a categorical variable with
4 levels in the initial analysis. In the Cox Proportional Haz-
ards models, we combined WHO stage 1 and 2, therefore
WHO stage was a categorical variable with 3 levels.
The status of children who were lost to follow-up in this
study was unknown. A meta-analysis of individual patient
data from HIV treatment programs in Sub-Sahara Africa
found that 20% of adults lost to follow-up were actually
deceased [19]. To evaluate the “worst case scenario” effect
of bias due to loss to follow-up on mortality, we performed
sensitivity analysis by assuming that all the children who
were lost to follow-up survived for 90 days after their last
visit and then died. We estimated the mortality rates for
this scenario at 3months, 6months, 1, 5 and 10 years and
compared with the main study results.
Data analysis was done using SAS version 9.4 (SAS In-
stitute Inc., Cary, NC) and R statistical software version
3.4 [20]. We used the Survival package to plot the KM
curves and Survminer package to visualize the KM
curves [21, 22].
Results
One thousand and thirty-nine (1039) children aged less
than 15 years commenced ART at LCH between January
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2003 and June 2015. Overall, 71 (7%) children were con-
firmed to have died after commencing treatment and 594
(56%) were alive and active in care at the time of this
study. A total of 164 (16%) were lost to follow-up and 210
(20%) transferred to other health care facilities (Fig. 1).
Baseline characteristics of children started on ART
At baseline, 520 (50%) children were female and 721
(69%) were cared for by their biological mothers. A total
of 179 (17%) children started treatment during their first
year of life. At least 304 (29%) children were diagnosed
during hospital admission and 30 (3%) were diagnosed
after delivery from the delivery wards (Table 1).
The median age at baseline was 3.6 years (IQR: 1.3–
8.6). The immunological criteria that was used to initiate
treatment for children older than 5 years was CD4 count
and the baseline median CD4 count was 505 (IQR: 243–
948) while CD4 percentage was used for children youn-
ger than 5 years. Children aged less than 1 year had me-
dian CD4 percentage of 19.4 (IQR: 12.4–25.6) and
children aged between 1 and 5 years had median CD4
percentage of 16.7 (IQR: 11.3–21.5). At least 1002 (97%)
took Cotrimoxazole at baseline and 301 (30%) had a
diagnosis of clinical Tuberculosis (TB) at ART initiation.
Overall, 472 (46%) were WHO stage 3 and 177 (17%)
were advanced WHO stage 4 (Table 2).
The first line regimen for 907 (87%) children was two
NRTIs and one NNRTI, and 54 (5%) were commenced
on two NRTIs and a Protease Inhibitor (Lopinavir
boosted with Ritonavir) while 78 (8%) children took
triple NRTIs at baseline, (Azido thymidine or Stavudine,
Lamivudine and Abacavir) (Table 2).
Mortality trends
A total of 71 deaths were documented during the study
period. The highest proportion of deaths occurred be-
tween 2007 and 2011 (Additional file 2). The largest
number of deaths were among young children aged less
than 12months (n = 29; 41%) (Fig. 2). Of the 71 de-
ceased children, 44% (n = 31) were WHO stage 4, 41%
(n = 29) were WHO stage 3, 8% (n = 6) were WHO stage
2 and 7% (n = 5) were WHO stage 1. We verified causes
of death from 27 (38%) death certificates. Of the verified
deaths 14% (n = 10) were due to diarrhea, 11% (n = 8) se-
vere pneumonia and protein energy malnutrition re-
spectively and 7% (n = 5) were due to TB (Table 3).
For an overall person-year of observation (PYO) of
4450 PY the mortality rate was 1.6/100 PYO (95%
CI:1.4–1.8). Mortality was highest within the first 3
months of treatment initiation with estimated mortality
rate of 11.9/100 PYO (95% CI:7.6–16.3), which
accounted for 41% (n = 29) of the deaths (Table 4). The
3-month survival probability was 0.97 (Fig. 3). After 10
years of treatment, the observed mortality rate was 1.6/
100 PYO (95% CI: (1.4–1.8).
In a sensitivity analyses that assumed the “worst case
scenario” that all children who were lost to follow-up died
90 days after their last clinic visit, the mortality rate after
3months of treatment was 14.5/100 person years (95% CI:
9.7–19.2). After 10 years of treatment, the mortality rate
was 5.4/100 person years (95% CI: 4.7–6.1) which is 5
times higher than actual observed mortality rate (Table 5).
Children who took triple NRTI regimens had the
shortest survival time (86% at 1 year) compared to chil-
dren who took 2NRTI+ 1NNRTI and protease inhibitor
based regimens (log rank test, p < 0.0001, Fig. 4 d). Other
baseline factors associated with shorter survival were:
children who had anemia at ART initiation (Hemoglobin
< 8 g/dl) (p = 0.032), children of mothers who did not
take antiretroviral drugs during pregnancy (p = 0.012),
severe wasting as estimated by WAZ score < -3SD (p =
0.051) and infants who were given ARVs for prophylaxis
(p = 0.056) (Additional file 3). Tuberculosis at baseline,
calendar year of ART initiation and whether the infant
took antiretroviral drugs for prophylaxis at enrollment
were not statistically significant in the univariable Cox
proportional hazards model and we did not include
them in the multivariable model (Table 6).
Infants who started ART within the first year of life ex-
perienced shorter survival time compared to those who
started treatment between 1 to 5 years and between 6 to
15 years of age (Fig. 4 a, log-rank test, p-value < 0.0001).
Fig. 1 Treatment outcomes and retention in care among children
on ART at LCH 2003–2015
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The survival probability for infants aged less than 1 year
was 0.93 after 3months of treatment compared to 0.96 for
those aged 1 to 5 years and 0.99 for those aged 6–15 years.
In the multivariable Proportional Hazards regression, the
adjusted hazards of death among children aged less than
1 year were 3.1 (95% CI: 1.3–6.4), and children aged 1–5
years aHR = 1.1 (95% CI: 0.6–2.3) when compared to the
referent group 6–15 years (Table 6).
Children with severe immune-suppression (WHO
stage 4) at baseline had lower survival probability of 93,
97% for the WHO stage 3 and 99% for WHO stage 1
and 2, (Fig. 4 b, log-rank test, p-value < 0.0001). In the
multivariable Proportional Hazards regression, children
with advanced WHO stage 4 had the highest hazards of
mortality (aHR = 4.8 (95% CI: 2.3–10) (p < .0001), WHO
stage 3 (aHR = 1.8 (0.9–3.6) p = 0.1188), compared to the
referent group WHO stage 1 and 2, (Table 6).
Discussion
In this study carried out in a routine pediatric HIV treat-
ment setting, we found that after 12 years of treatment
(2003–2015) attrition due to death was low (7%; n = 71).
Death was highest within the first 3 months of starting
ART (mortality rate: 11.7/100 PYO; 95% CI:7.6–16.3).
The hazard of death was highest among children aged
less than 12 months (aHR: 3.1: 95% CI: 1.3–6.4), com-
pared to the referent group 6–15 years. Loss to
follow-up was high (16%; n = 164).
The mortality rate observed in this study was much
lower than that observed in other parts of Zambia [8,
Table 1 Baseline Characteristics of infants and Children who Received ART by Age Group - Livingstone Central Hospital, Zambia
(2003–2015)
Characteristic < 1 year 1–5 years 6–15 years Total
N = 179 (17%) N = 387 (37%) 473 (46%) N = 1039
Gender n(%)
Female 84 (16%) 182 (35%) 254 (49%) 520
Male 95 (18%) 205 (40%) 219 (42%) 519
Age(years) at ART initiation Median (IQR) 0.5 (0.3–0.8) 2.0 (1.4–3.2) 10.2 (7.4–13) 3.6 (1.3–8.6)
Duration (years) on treatment Median(IQR) 2.1 (0.5–5.2) 4.2 (1.2–6.5) 4.1 (1.9–6.7) 3.8 (1.2–6.5)
Duration of time (weeks) from diagnosis to ART initiation Median (IQR) 7 (2–11) 5 (2–15) 7 (2–39) 6 (2–19)
Who is the child’s Guardian
Mother 150 (21%) 316 (44%) 255 (35%) 721
Father 5 (11%) 8 (18%) 30 (68%) 44
Grandparent 6 (8%) 24 (32%) 46 (61%) 76
Sibling 0 1 (6%) 14 (88%) 16
other relative 5 (4%) 22 (17%) 99 (79%) 126
missing 13 (22%) 16 (28%) 29 (50%) 56
Point of Entry into HIV care
Out-patients departments 22 (13%) 44 (25%) 110 (63%) 176
Inpatient Wards 80 (26%) 152 (50%) 72 (24%) 304
Delivery wards 30 (100%) 0 0 30
VCT clinic(FSU) 11 (9%) 42 (33%) 72 (57%) 127
TB clinic 3 (25%) 3 (25%) 6 (50%) 12
missing 58 (15%) 129 (33%) 205 (52%) 390
Educational level of caregiver
None 2 (10%) 11 (58%) 6 (52%) 19
Primary or secondary school 113 (18%) 226 (37%) 272 (44%) 612
Some college or university 11 (18%) 16 (27%) 32 (53%) 60
missing 53 (15%) 134 (38%) 163 (47%) 348
Does the family have a phone
Yes 102 (14%) 243 (35%) 358 (51%) 705
Has HIV status been disclosed to the child
Yes 0 0 191 (100%) 191
Mutanga et al. BMC Public Health          (2019) 19:115 Page 5 of 12
Table 2 Baseline laboratory and clinical features of infants and children who received ART at Livingstone Central Hospital, Zambia
(2003–2015)
Characteristics < 1 year 1–5 years 6–15 years Total
N = 179 (17%) N = 387 (37%) N = 473 (46%) N = 1039
CD4 count at enrollment Median (IQR) 1028 (535–1498) 777 (444–1135) 278 (118–487) 505 (243–948)
CD4 percent at enrollment Median(IQR) 19.4 (12.4–25.6) 16.7 (11.3–21.5) 14.0 (8.3–21.2) 16.2 (10–23)
Hemoglobin at enrollment (Median IQR)) 8.8 (7.8–9.7) 9.3 (8.0–10.5) 10.3 (9–11.5) 9.6 (8.3–10.9)
Taking Cotrimoxazole at enrollment
Yes 169 (17%) 378 (38%) 451 (45%) 1000
No 9 (23%) 8 (21%) 22 (56%) 39
Drug regimen at ART initiation N(%)
3 NRTI’s 30 (38%) 46 (59%) 2 (3%) 78
2NRTIs +1NNRTI 130 (14%) 320 (35%) 457 (50%) 907
LPV/r based 19 (35%) 21 (39%) 14 (26%) 54
Year of ART start N(%)
2003–2005 3 (4%) 17 (24%) 51 (72%) 71
2006–2009 88 (17%) 202 (39%) 222 (43%) 512
2010–2012 62 (20%) 117 (38%) 126 (41%) 305
2013–2016 26 (17%) 51 (34%) 74 (49%) 151
Mom took ARVs for PMTCT during pregnancy
Yes 69 (45%) 71 (46%) 14 (9%) 154
No 110 (12%) 316 (36%) 459 (52%) 885
Child took ARV prophylaxis after birth N(%)
Yes 55 (43%) 58 (47%) 8 (10%) 123
No 124 (14%) 329 (36%) 463 (51%) 810
Nutritional status at enrollment
Weight for height score < -3SD 36 (20%) 88 (48%) 58 (32%) 182
weight for height score > −3 SD 143 (17%) 299 (35%) 415 (48%) 857
Baseline clinical staging (WHO stage) N(%)
WHO stage 1 52 (24%) 64 (29%) 103 (47%) 219
WHO stage 2 20 (13%) 39 (25%) 99 (63%) 158
WHO stage 3 65 (14%) 200 (43%) 206 (44%) 471
WHO stage 4 41 (23%) 78 (44%) 58 (33%) 177
missing 1 6 7 14
Diseases at baseline N(%)
TB 33 (10%) 105 (33%) 178 (56%) 318
pneumonia 35 (21%) 68 (41%) 61 (27%) 165
Diarrhea 45 (18%) 117 (47%) 84 (34%) 247
Gestation age at birth N(%)
Premature 4 (25%) 8 (50%) 4 (25%) 16
term 107 (22%) 201 (41%) 175 (36%) 485
unknown 68 (13%) 178 (33%) 294 (54%) 544
Mode of delivery N(%)
C/Section 5 (28%) 3 (17%) 10 (56%) 18
SVD 105 (21%) 206 (42%) 180 (37%) 491
unknown 69 (13%) 178 (34%) 283 (53%) 530
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23]. In a study conducted in an urban area in Zambia,
the mortality rate was 6.6/100 PYO over 3018 PYO [8]
and another study in a rural area in Zambia found a high
mortality of 14.4% after 6 months of treatment [23].
These 2 studies were characterized by high mortality
within the first 3 months (17.4/100 PYO) and the associ-
ated risk factors were similar to what we observed [8].
Mortality rates in our study population were also similar
to a study from a rural setting in Malawi where 12
months mortality rate was 6.6/100 PYO [95% CI: 5.5–
7.9] and overall mortality was 3.4/100 PYO [95% CI:2.9–
4] after 5 years of follow-up [24]. Our observed mortality
rate is however higher than findings from developed
countries where 10-year mortality was as low as 0.3/100
PYO in the Dutch cohort [25].
The observation that hazards of death were highest
within the first few months after ART initiation and then
declines after the first 6 months of treatment is consist-
ent with studies done in other parts of Zambia and in
similar settings [8, 26–28]. Other studies have attributed
the high early mortality to late presentation to care [29].
Studies done in routine clinic settings in resource
limited settings found that the cumulative incidence
of mortality during the first year of treatment among
older children between 5 and 10 years of age was less
than 2% to more than 45% among infants aged less
than 12 months with severe disease [10]. Once chil-
dren get past the initial 6 months of ART, their risk
of mortality declines to very low rates especially when
adherence to treatment and follow-up is optimized
[11, 27, 30].
Our finding that the hazards of mortality were highest
among infants and children aged less than 12months of
age is consistent with predictive models that have been
done in both developed and developing countries and in
fact motivated the universal ART policy by WHO to test
and treat all HIV-exposed infants and children [31]. Results
of a modelling study done in six countries in Sub-Sahara
Africa suggested that mortality is higher among perinatally
HIV-infected children than those infected through breast-
feeding [32]. Perinatally HIV-infected infants have a higher
risk of mortality and disease progression [5]. Early diagnosis
of HIV infection and early initiation of ART improves the
outcomes of infants and children [33]. Although early in-
fant diagnosis of HIV is critical, there are still challenges in
resource limited settings to diagnose children. Children
who are missed by the PMTCT programs are at highest
risk of mortality because they usually present to the hospital
after an illness when they are already immunocompromised



























Fig. 2 Age at time of Death Among 71 Deceased Children on ART: Livingstone Central Hospital, Zambia (2003–2015)
Table 3 Cause of death as recorded on death certificate
Cause of death Total number
Diarrhea 10
Severe Pneumonia 8






We found death certificates of 27 patients. The cause of death as recorded on
the death certificate is listed in the table above
Some patients had more than one cause of death listed on the
death certificate
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We assessed the causes of death in our study but only
found death certificates for 27 children and no postmor-
tem or thorough investigations had been done to ascer-
tain cause of death. However, causes of death recorded
on the few death certificates were similar to the causes
of childhood deaths in Zambia, which are diarrhea, se-
vere pneumonia and protein energy malnutrition [35].
This setting has a very high infant mortality rate (65/
1000 in 2015) [36]. In the pre-ART era, AIDS related
deaths led to an increase in infant mortality in high HIV
burden countries. Antiretroviral therapy improved child
survival and evidence is now showing that early initi-
ation of ART leads to better clinical outcomes [33]. In a
study that pooled results of clinical trial data from
Zimbabwe and Uganda, the mortality risk was attributed
to pre-ART risks that persist until the antiretroviral
drugs reach their maximal effectiveness [27]. These early
deaths have been attributed to suboptimal management
of malnutrition, Tuberculosis and other related medical
conditions during the early treatment stage including
Immune Reconstitution Syndrome (IRIS) [11]. However,
the role of IRIS in mortality during the early months of
treating HIV seropositive children with ART is poorly
understood [37]. Our study had insufficient evidence to
support the role of IRIS as a risk factor of early
mortality.
The major strength of our study is that it was done in
a routine clinic setting among children commencing
ART in a high HIV burden setting. This provides a
real-world effectiveness of pediatric HIV treatment out-
comes and provides information on important predictors
of mortality. Our sample size was large and we had
enough outcomes to make reasonable conclusions.
Table 4 Mortality among children receiving ART at Livingstone Central Hospital, (2003–2015)
Duration of cART Number of children left Deaths Follow-up years Mortality Rate, deaths per 100 person-years (95% CI)
3 months 927 29 243 11.9 (7.6–16.3)
6 months 868 41 469 8.7 (6.0–11.41)
1 year 813 49 894 5.5 (3.9–7.1)
2 years 702 60 1646 3.6 (2.7–4.5)
5 years 385 66 3293 2.0 (1.5–2.5)
10 years 25 71 4450 1.6 (1.4–1.8)
Fig. 3 KM Survival plot of time to death after ART initiation: Livingstone Central Hospital, Zambia (2003–2015)
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A major limitation is that there was a high proportion
of loss to follow-up (16%) and many transfers (20%).
This made ascertainment of mortality very challenging
because some of the children who were lost to follow-up
may be deceased and therefore misclassified and the
mortality rates that we observed may be an underesti-
mate. The estimated mortality rates under the “worst
case scenario” assumption that all children who were
lost to follow-up had died was 7 times higher after 1 year
of follow-up and 5 times higher after 10 years of
follow-up. A study from Malawi found that only 11% of
the children who were lost to follow-up had died [13].
This study was done in an urban setting unlike our study
setting which is both urban and rural. Our sensitivity
analysis approach allowed us to estimate maximum mor-
tality rates which was more informative in our setting.
Table 5 Sensitivity analysis - effect of bias due to loss to follow-up – worst case scenario
Duration of cART Number of children left Deaths Follow-up years Mortality Rate, deaths per
100 person-years (95% CI)
3 months 956 36 248 14.5 (9.7–19.2)
6 months 901 68 478 14.2 (10.8–17.6)
1 year 822 106 908 11.6 (9.4–13.9)
2 years 710 145 1672 8.7 (7.2–10.8)
5 years 387 200 3326 6.0 (5.1–6.9)
10 years 25 229 4225 5.4 (4.7–6.1))
We assumed that all the patients who were lost to follow-up survived for 90 days after their last clinical visit then died
Fig. 4 a-4d: 4A-Age at enrollment, 4b, WHO stage at enrollment, 4c, HIV disclosure at enrollment, 4d: ART regimen at Baseline
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Table 6 Factors Associated with Mortality Among Children on ART at Livingstone Central Hospital (2003–2015)
Predictor N Deaths Unadjusted Mortality HR (95% CI) p-value Adjusted Mortality HR (95% CI) p-value
Gender (N%)
Male 519 33 Ref
Female 520 38 1.17 (0.7–1.9) 0.5207
Baseline age
< 1 year 179 29 5.4 (2.9–9.9) <.0001 3.1 (1.3–6.4) 0.0034
1-5 years 387 25 1.9 (1.03–3.5) 0.0423 1.1 (0.6–2.3) 0.7529
5–15 years 473 17 Ref Ref
Year of ART Initiation
2003–2005 71 2 0.3 (0.03–2.7) 0.2778
2006–2009 512 43 2.1 (0.8–5.9) 0.1534
2010–2012 305 22 2.0 (0.7–5.9) 0.1948
2013–2014 151 4 Ref
Nutritional status at baseline
Wasted (WAZ < =-3SD) 182 17 Ref Ref
WAZ > -3SD 857 54 0.59 (0.3–1.02) 0.0564 0.8 (0.6–1.5) 0.5141
CD4%
< 15% 139 22 3.2 (0.9–10.8) 0.0561
15–25% 285 18 2.9 (0.8–9.9) 0.08
> =25% 225 3 Ref
missing 390 28 3.1 (0.9–10.2)
Baseline Hemoglobin
< =8 705 40 1.68 (1.05–2.69) 0.0295 1.2 (0.8–2.0) 0.4025
> 8 334 31 Ref Ref
WHO stage at baseline
stage 1 and 2 377 11 Ref Ref
stage 3 471 29 2.05 (1.01–4.06) 0.0452 1.8 (0.9–3.6) 0.1188
stage 4 177 29 6.41 (3.19–12.85) <.0001 4.8 (2.3–10) <.0001
missing 14 0
TB at baseline
Yes 318 21 0.82 (0.54–1.49) 0.6645
No 721 50 Ref
Regimen at baseline
1NNRTI + 2NRTi’s 907 53 0.26 (0.14–0.46) <.0001 Ref
3 NRTI’s 54 4 0.37 (0.12–1.12) 0.0789 1.9 (0.9–3.7) 0.0603
LPV/R based regimen 78 14 Ref 0.9 (0.3–2.6) 0.806
Mother took ART for PMTCT
Yes 154 17 Ref Ref
No 885 54 1.9 (1.2–3.4) 0.0139 1.0 (0.1–1.05) 0.0627
aChild know HIV status
Yes 191 4 0.21 (0.08–0.6) 0.0029 Ref
No 848 67 Ref 0.4 (0.1–1.05)
aApplies to older children aged above 7 years’ old
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Transfers are high in this clinic, which is motivated by
Ministry of Health policy that encourages people to seek
care at the health facility nearest to them. Studies have
showed that this is an effective strategy as patients can
additionally benefit from support groups and other pro-
grams that may be available at their nearest health facil-
ity [38, 39]. However, this makes it difficult to study
long-term treatment outcomes because patient tracking
is impossible once they transfer to another facility.
Conclusion
We observed low attrition due to mortality among chil-
dren on ART in Zambia. Loss to follow-up was high
(16%) and could underestimate the mortality. Mortality
was highest during the first 3 months of treatment. Chil-
dren aged less than one year and children with advanced
WHO disease stage had higher mortality. We recom-
mend to program managers and clinicians to develop ef-
fective interventions to improve retention in care and
strengthen early infant diagnosis of HIV. Pretreatment
screening and treatment of opportunistic infections
among children commencing ART needs to be strength-
ened to reduce early mortality.
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